Comparative Pharmacology
Head-to-head clinical analysis: FUNDUSCEIN 25 versus THYROGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNDUSCEIN 25 versus THYROGEN.
FUNDUSCEIN-25 vs THYROGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluorescein sodium absorbs blue light (465–490 nm) and emits yellow-green fluorescence (520–530 nm), allowing visualization of retinal and choroidal vasculature. It binds to serum proteins and leaks from abnormal blood vessels, highlighting areas of neovascularization or edema.
Recombinant human thyroid-stimulating hormone (TSH) that binds to TSH receptors on thyroid follicular cells, stimulating iodine uptake, thyroglobulin synthesis, and release of thyroid hormones.
0.5 mL of FUNDUSCEIN-25 (25 mg/mL) administered intravenously as a single bolus injection over 5-10 seconds.
0.9 mg intramuscular injection every 24 hours for 2 doses, or 1.2 mg orally as a single dose.
None Documented
None Documented
Terminal elimination half-life is approximately 26 minutes in adults (range 20–30 minutes). Clinical context: Rapid clearance allows repeated injections within 30–60 minutes if needed.
12-15 hours (terminal elimination half-life in patients with normal renal function; may be prolonged in renal impairment). Clinically, TSH levels peak by 3 hours after IM injection and return to baseline by 24-48 hours.
Primarily renal elimination of unchanged fluorescein and its glucuronide conjugate (80% within 24 hours). Biliary/fecal excretion accounts for <5%.
Primarily renal (thyrotropin is a glycoprotein hormone; intact hormone is minimally excreted unchanged; metabolic degradation products are eliminated renally). After IV administration, approximately 96% of the dose is recovered in urine within 24 hours as low molecular weight degradation products. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Diagnostic Agent
Diagnostic Agent